ddo-2 Antibody

What is DDO protein and what is its significance in biological research?

DDO (D-aspartate oxidase) is a peroxisomal flavoprotein that catalyzes the oxidative deamination of D-aspartate and N-methyl D-aspartate. It requires flavin adenine dinucleotide or 6-hydroxyflavin adenine dinucleotide as cofactors for this reaction. The significance of DDO lies in its role in D-amino acid metabolism, which has implications for various physiological processes. Several transcript variants encoding different isoforms have been identified for the DDO gene, suggesting diverse functional roles. Understanding DDO biology is particularly important for neuroscience research, as D-amino acids serve as signaling molecules in the nervous system .

What are the key specifications of the DDO-2 antibody?

The DDO-2 antibody (catalog #A06611-2) is a polyclonal antibody raised in rabbits against E.coli-derived human DDO recombinant protein (Position: M1-P365). It has demonstrated reactivity with human, mouse, and rat DDO, making it suitable for cross-species research applications. The antibody is provided in liquid form at a concentration of 500 μg/ml in PBS with 0.02% NaN3, 1 mg BSA, and 50% glycerol. Its validated applications include Western blot (WB), immunoprecipitation (IP), and ELISA techniques .

How is DDO-2 antibody distinguished from antibodies targeting related enzymes?

DDO-2 antibody specifically recognizes D-aspartate oxidase, which must be distinguished from related flavin-containing amino acid oxidases, particularly L-amino acid oxidases (LAOs). The key distinction lies in the stereospecificity of these enzymes. While DDO is selective for D-amino acids, LAOs specifically oxidize L-amino acids. This stereospecificity is determined by the spatial arrangement of active site residues. Molecular studies have revealed that the active sites of D-amino acid oxidases and L-amino acid oxidases exhibit a mirror-plane relationship, with key catalytic residues (such as an invariant arginine that interacts with the Cα-carboxyl moiety) positioned to accommodate oppositely configured substrates . When validating DDO-2 antibody specificity, researchers should consider this structural relationship and include appropriate controls to confirm selective recognition of DDO.

What are the optimal protocols for using DDO-2 antibody in Western blot applications?

For Western blot applications using DDO-2 antibody, the following protocol optimizations are recommended:

• Sample preparation: The calculated molecular weight of DDO is approximately 37.535 kDa. Standard SDS-PAGE using 10-12% gels is suitable for resolving this protein.

• Antibody dilution: The recommended dilution range is 1:500-2000. Initial optimization experiments should test multiple dilutions to identify the optimal concentration for specific sample types .

• Blocking conditions: 5% non-fat dry milk or BSA in TBST is typically effective for reducing background.

• Incubation conditions: Overnight incubation at 4°C typically provides optimal results, especially for tissues with lower DDO expression.

• Detection system: Both chemiluminescent and fluorescent detection systems are compatible with this antibody.

• Controls: Include positive controls (tissues known to express DDO) and negative controls to validate specificity.

How can the DDO-2 antibody be used to investigate DDO in cellular and tissue contexts?

DDO-2 antibody can be employed in various experimental approaches to study DDO in cellular and tissue contexts:

• Tissue expression profiling: Western blot analysis across multiple tissues can establish expression patterns of DDO, which is particularly relevant for comparative studies in neural tissues versus peripheral tissues.

• Subcellular localization: Given that DDO is a peroxisomal protein, fractionation studies followed by immunoblotting can confirm its localization and potential mislocalization in disease states.

• Protein interactions: Immunoprecipitation using DDO-2 antibody can identify interaction partners, providing insights into DDO's functional networks.

• Expression in disease models: Changes in DDO expression can be monitored in models of neurological disorders, aging, or metabolic diseases.

• Correlation with enzymatic activity: Combining immunodetection with enzymatic assays can reveal relationships between protein levels and functional activity.

What methodological considerations are important when developing ELISAs with DDO-2 antibody?

When developing ELISA assays using DDO-2 antibody, the following considerations are important:

• Assay format: The polyclonal nature of the antibody makes it suitable for both direct and sandwich ELISA formats.

• Antigen capture: For direct ELISAs, coating conditions (buffer, pH, temperature) should be optimized to ensure efficient antigen binding to the plate.

• Antibody concentration: Titration experiments should be performed to determine optimal primary and secondary antibody concentrations.

• Standard curve: Recombinant DDO protein can serve as a standard for quantitative assays.

• Validation: Cross-reactivity testing should be conducted, particularly when working with complex biological samples.

• Detection system: HRP-based colorimetric detection is commonly used, but fluorescent or chemiluminescent systems may provide enhanced sensitivity.

How can DDO-2 antibody contribute to neuroscience research?

DDO-2 antibody offers several applications in neuroscience research:

• D-amino acid metabolism: DDO plays a critical role in metabolizing D-aspartate and D-serine, which function as neuromodulators in the brain. The antibody enables researchers to study regional and developmental variations in DDO expression, correlating these with D-amino acid levels.

• Neurological disorders: Altered D-amino acid metabolism has been implicated in conditions like schizophrenia, Alzheimer's disease, and epilepsy. DDO-2 antibody can detect changes in DDO expression in disease models and human samples.

• Neuroinflammation: D-amino acids and their metabolites may influence inflammatory processes in the CNS. Combining DDO-2 antibody with markers of inflammation can reveal potential associations.

• Synaptic plasticity: D-aspartate is involved in NMDA receptor modulation and synaptic plasticity. DDO-2 antibody can help investigate the regulation of D-aspartate availability at synapses.

What is the relevance of DDO in glycation research, and how can DDO-2 antibody be applied?

It's important to note that in glycation research, "DDO" commonly refers to dideoxyosones, which are distinct from D-aspartate oxidase (also abbreviated as DDO). This terminological overlap can cause confusion. Dideoxyosones are intermediates formed during the Maillard reaction (glycation) that contribute to advanced glycation end product (AGE) formation.

For clarity in glycation research:

• Dideoxyosones (DDO) are formed by the long-range carbonyl shift of the Amadori product and are major precursors of AGEs, including pentosidine and glucosepane, which accumulate in cataractous lenses .

• Detection methods: Dideoxyosones can be detected using o-phenylenediamine (OPD) to produce quinoxalines. Monoclonal antibodies against these quinoxaline derivatives have been developed for immunodetection .

• Experimental approach: Researchers should clearly distinguish between D-aspartate oxidase and dideoxyosone intermediates in their experimental design and terminology to avoid confusion.

How can DDO-2 antibody be utilized in vaccine immunology research?

In vaccine immunology research, it's important to distinguish between DDO (D-aspartate oxidase) and DDO (DVG-derived oligonucleotide) used as vaccine adjuvants:

• DVG-derived oligonucleotide (DDO): This is a 268nt oligonucleotide derived from Sendai virus defective viral genomes that functions as an adjuvant in vaccines. It stimulates RIG-I-like receptor signaling, leading to type-1 immunity during vaccination .

• Immunological effects: When used as an adjuvant with inactivated influenza virus (IAV) vaccines, this DDO induces a robust IgG2c antibody response, characteristic of type-1 immunity, as opposed to the IgG1 response typically seen with aluminum-based adjuvants (Alum) .

• T-cell responses: DDO adjuvants enhance both Th1 and CD8+ T-cell responses, providing superior protection against heterosubtypic viral challenges compared to traditional adjuvants .

For researchers studying vaccine immunology, it's essential to clearly define which DDO is being referenced in experimental protocols and publications.

What are common challenges when using DDO-2 antibody, and how can they be addressed?

Researchers may encounter several challenges when working with DDO-2 antibody:

How should researchers interpret discrepancies between DDO protein levels and enzymatic activity?

Discrepancies between DDO protein expression (detected by DDO-2 antibody) and enzymatic activity may arise from several factors:

• Post-translational modifications: Modifications may affect enzyme activity without altering antibody recognition.

• Cofactor availability: DDO requires FAD as a cofactor; insufficient cofactor availability could result in enzymatically inactive protein.

• Inhibitory molecules: Endogenous inhibitors may be present in biological samples, suppressing activity without affecting protein levels.

• Protein folding: The antibody may detect misfolded protein that lacks catalytic activity.

• Assay conditions: Suboptimal conditions in enzymatic assays may not reflect the true catalytic potential of the detected protein.

To address these discrepancies, researchers should:

• Include FAD supplementation in activity assays

• Analyze protein under both native and denaturing conditions

• Consider the influence of sample preparation on enzymatic activity

• Examine potential post-translational modifications using additional techniques

What are the storage and handling recommendations to maintain DDO-2 antibody activity?

To maintain optimal activity of DDO-2 antibody:

• Storage temperature: Store at -20°C for long-term stability (up to 12 months from date of receipt).

• Working storage: After reconstitution, the antibody can be stored at 2-8°C for up to 6 months.

• Freeze-thaw cycles: Avoid repeated freezing and thawing, which can lead to protein denaturation and reduced activity.

• Aliquoting: Upon receipt, consider preparing small aliquots for single-use to minimize freeze-thaw cycles.

• Working solutions: Diluted antibody solutions should be prepared fresh for each experiment when possible.

• Contamination prevention: Use sterile technique when handling the antibody to prevent microbial contamination .

How can DDO-2 antibody be integrated with other techniques for comprehensive DDO research?

For advanced DDO research, integration of DDO-2 antibody with complementary techniques provides more comprehensive insights:

• Proteomics integration:

  • Immunoprecipitation with DDO-2 antibody followed by mass spectrometry to identify interaction partners

  • Parallel analysis of post-translational modifications using modified-residue-specific antibodies

• Genomic correlation:

  • Combined analysis of DDO protein levels with gene expression data

  • Integration with genetic variation studies (SNPs, mutations) affecting DDO expression or function

• Metabolomic connections:

  • Correlation of DDO protein levels with D-amino acid concentrations measured by HPLC or mass spectrometry

  • Assessment of downstream metabolic pathways affected by DDO activity

• Imaging applications:

  • Colocalization studies with peroxisomal markers in fluorescence microscopy

  • Live cell imaging using DDO-GFP fusions validated with the antibody

• Functional assays:

  • Parallel analysis of DDO enzymatic activity and protein expression

  • Assessment of cellular responses to DDO manipulation (overexpression, knockdown)

What considerations are important when studying DDO in the context of oxidative stress?

When investigating DDO in oxidative stress contexts, researchers should consider:

• Dual roles: DDO enzymatic activity generates H₂O₂, which can contribute to oxidative stress while also serving as a signaling molecule.

• Peroxisomal homeostasis: Oxidative stress can impact peroxisome function and number, potentially affecting DDO localization and activity.

• Protein stability: Oxidative conditions may modify DDO structure, affecting both antibody recognition and enzymatic function.

• Experimental design considerations:

  • Include markers of oxidative damage alongside DDO analysis

  • Consider the timing of oxidative stress induction relative to DDO assessment

  • Evaluate both soluble and membrane-associated DDO pools, as oxidative stress can alter protein solubility

• Methodological approaches:

  • Compare DDO detection under reducing and non-reducing conditions

  • Assess peroxisomal integrity using additional markers

  • Include antioxidant treatments to determine reversibility of observed effects

How might DDO research contribute to understanding amino acid stereospecificity in biological systems?

DDO research offers insights into the biological significance of amino acid chirality:

• Evolutionary perspectives: DDO and LAO (L-amino acid oxidases) represent evolutionary adaptations to handle different stereoisomers of amino acids. The mirror-plane relationship in their active sites demonstrates how protein structure has evolved to accommodate substrate chirality .

• Stereospecific metabolism: DDO specifically oxidizes D-amino acids, regulating their concentrations in various tissues. This stereospecificity highlights biological mechanisms for discriminating between amino acid enantiomers.

• Physiological roles: By controlling D-amino acid levels, DDO influences processes where these amino acids serve as signaling molecules, neurotransmitters, or bacterial components.

• Research applications:

  • Use DDO-2 antibody to track expression changes in response to D-amino acid challenges

  • Compare stereospecific enzymatic activities across tissues and developmental stages

  • Investigate potential regulatory mechanisms that coordinate D- and L-amino acid metabolism

• Clinical relevance: Altered D/L amino acid ratios have been implicated in various pathological conditions, making DDO a potential target for therapeutic interventions or diagnostic approaches.